Rani Therapeutics Holdings, Inc. insider trading

Every open-market purchase and sale by Rani Therapeutics Holdings, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $1.3M 3 trades by 2 insiders 3 months later: median −8.0% (−11.0% vs S&P 500) Insider sales, 5 years $15.7M 4 trades by 3 insiders 3 months later: median −23.7% (−33.0% vs S&P 500)

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Rani Therapeutics Holdings, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Rani Therapeutics Holdings, Inc.’s insiders pay?

From August 19, 2022 to July 23, 2026, 9 insiders reported 47 open-market purchases and 6 sales not made under a pre-set plan in Rani Therapeutics Holdings, Inc. Twelve months after each purchase was reported, the shares were −68.6% against the S&P 500 on average (median −75.7%), over 31 purchases with a full year of prices; 7% beat the index. After sales, the shares moved −73.4% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 3, 2022 into $11,168 by November 2, 2026, +2.8% a year. It held shares 36% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $15,226 (+11.2% a year), and held throughout $21,475 (+21.2%).

Copying Rani Therapeutics Holdings, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Rani Therapeutics Holdings, Inc.'s insiders from November 3, 2022, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 36% of the time.

Rani Therapeutics Holdings, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
South Lake One LLC	10% owner	21	−67.9% (18)	6%	0	—	May 15, 2023
South Cone Investments Limited Partnership	10% owner	14	−65.2% (10)	10%	2	—	October 22, 2025
Imran Talat	Chief Executive Officer	5	—	—	1	—	July 21, 2026
Imran Mir A	Director	2	—	—	1	−73.4% (1)	July 23, 2026
Aequanimitas Limited Partnership	10% owner	1	−75.4% (1)	0%	1	—	December 8, 2023
Quiroga Cortes Isidoro Alfonso	10% owner	2	−88.8% (2)	0%	0	—	November 7, 2022
Butel Jean Luc	Director	1	—	—	0	—	November 21, 2023
Farquharson Andrew	Director	0	—	—	1	−73.4% (1)	August 19, 2022
Mckinley Kate	Chief Business Officer	1	—	—	0	—	December 16, 2024

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Rani Therapeutics Holdings, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Rani Therapeutics Holdings, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −51.7% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
November 30, 2022	3 buying	−23.5%	−51.7%	−84.9%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Rani Therapeutics Holdings, Inc. · Funds · Politicians